thalidomide has been researched along with Weight Gain in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase II trial is beginning using thalidomide as a treatment for chronic diarrhea in HIV-infected patients." | 9.08 | Thalidomide for diarrhea. ( , 1996) |
| "Thalidomide treatment was well tolerated, without serious adverse events." | 6.68 | Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. ( Akarasewi, P; Burroughs, M; Johnson, B; Kaplan, G; Klausner, JD; Makonkawkeyoon, S; Molloy, A; Rom, W; Tramontana, JM; Utaipat, U, 1995) |
| "A phase II trial is beginning using thalidomide as a treatment for chronic diarrhea in HIV-infected patients." | 5.08 | Thalidomide for diarrhea. ( , 1996) |
| "Oesophageal cancer cachexia is a significant clinical problem, resulting in excessive morbidity and mortality." | 2.76 | Poor tolerability of thalidomide in end-stage oesophageal cancer. ( Cole, AT; Freeman, JG; Khan, ZH; Rennie, MJ; Selby, AL; Wilkes, EA, 2011) |
| "Thalidomide treatment was well tolerated, without serious adverse events." | 2.68 | Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. ( Akarasewi, P; Burroughs, M; Johnson, B; Kaplan, G; Klausner, JD; Makonkawkeyoon, S; Molloy, A; Rom, W; Tramontana, JM; Utaipat, U, 1995) |
| "The methods used in treatment of osteoporosis induced by glucocorticosteroids are not effective enough." | 1.38 | Effects of thalidomide on the development of bone damage caused by prednisolone in rats. ( Kaczmarczyk-Sedlak, I; Rotko, K; Sedlak, L; Zych, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilkes, EA | 1 |
| Selby, AL | 1 |
| Cole, AT | 1 |
| Freeman, JG | 1 |
| Rennie, MJ | 1 |
| Khan, ZH | 1 |
| Kaczmarczyk-Sedlak, I | 1 |
| Zych, M | 1 |
| Rotko, K | 1 |
| Sedlak, L | 1 |
| Teo, S | 1 |
| Noormohamed, F | 1 |
| Youle, M | 1 |
| Johnson, M | 1 |
| Peters, B | 1 |
| Stirling, D | 1 |
| Thomas, S | 1 |
| Tramontana, JM | 1 |
| Utaipat, U | 1 |
| Molloy, A | 1 |
| Akarasewi, P | 1 |
| Burroughs, M | 1 |
| Makonkawkeyoon, S | 1 |
| Johnson, B | 1 |
| Klausner, JD | 2 |
| Rom, W | 1 |
| Kaplan, G | 1 |
| Sharp, M | 1 |
| Getty, J | 1 |
| Lowell, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for thalidomide and Weight Gain
| Article | Year |
|---|---|
Poor tolerability of thalidomide in end-stage oesophageal cancer.
Topics: Aged; Aged, 80 and over; Cachexia; Double-Blind Method; Esophageal Neoplasms; Female; Humans; Male; | 2011 |
Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
Topics: Adult; Aged; Cells, Cultured; Cytokines; Humans; Hypersensitivity, Delayed; Immunosuppressive Agents | 1995 |
Thalidomide for diarrhea.
Topics: Diarrhea; HIV Infections; Humans; Quality of Life; Thalidomide; Tumor Necrosis Factor-alpha; Weight | 1996 |
6 other studies available for thalidomide and Weight Gain
| Article | Year |
|---|---|
Effects of thalidomide on the development of bone damage caused by prednisolone in rats.
Topics: Administration, Oral; Animals; Bone Remodeling; Dose-Response Relationship, Drug; Femur; Glucocortic | 2012 |
Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Thalidomide; Viral | 2002 |
Thalidomide use is associated with weight gain in HIV-1-positive clients.
Topics: Adult; Female; HIV Infections; HIV Wasting Syndrome; HIV-1; Humans; Immunosuppressive Agents; Male; | 1997 |
Growing interest in thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cells, Cultured; Clinical Trials as Topic; Female; Humans | 1995 |
Thalidomide study.
Topics: Clinical Trials as Topic; Drug Approval; HIV Wasting Syndrome; Humans; Oral Ulcer; Placebos; Pregnan | 1997 |
The thalidomide comeback.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infection | 1998 |